Alloantibodies are induced antibodies that limit the availability and success of heart and lung allotransplantation. In the presently funded period, we have demonstrated that mice presensitized to alloantigens can be rendered tolerant to these antigens using a non-myeloablative regimen for mixed chimerism induction. However, chimerism induction is markedly impeded by the presence of anti-donor alloantibodies. In the proposed renewal of this project, we will address this problem in both the mouse model and a novel humanized mouse model that we have developed, with the goal of developing a clinically relevant mixed chimerism regimen that will overcome both T and B cell sensitization to the donor. We will:
Aim 1 : Identify the cell types producing anti-donor alloantibodies in presensitized mice and develop methods of depleting them. This information will then be applied to the development of a non-myeloablative mixed chimerism regimen that overcomes both pre-sensitized T cell and alloantibody responses, allowing vascularized heart transplantation in presensitized hosts;
Aim 2 : Identify the human cell types with potential to produce alloantibodies in presensitized humanized mice and develop methods of depleting them. We will develop a protocol for mixed allogeneic chimerism induction in humanized mice and extend this approach to the allopresensitized setting. Natural antibodies (Nab) limit the success of both allogeneic and xenogeneic transplantation. Nab recognition of blood group antigens and of autoantigens exposed by ischemia-reperfusion injury can induce hyperacute and acute humoral rejection and promote other forms of rejection. We have demonstrated grant that mixed chimerism leads to tolerance of anti-carbohydrate (aGal) Nab-producing B cells by an anergy mechanism that is later followed by deletion of donor-reactive B cells. This tolerance is dependent on complement receptor expression by non-hematopoietic cells of the recipient. We hypothesize that tolerance of the B-1b B cells producing Nabs requires interactions with splenic follicular dendritic cells (FDCs) that pick up immune complexes via their complement receptors.
Aim 3 : Determine the role of secreted Ig and complement receptors in the tolerization of natural antibody-producing cells. We will address the hypothesis that immune complexes formed by natural antibodies to donor antigens and complement components target the Nab-producing B cells to FDCs in the spleen, providing a critical activation step that renders the cells susceptible to subsequent anergy and ultimate deletion upon repeated encounter with cell surface-bound antigen on donor-derived hematopoietic cells. _^_____

Public Health Relevance

(Seeinstructions): Together, the studies in this project will allow the improved application of the mixed chimerism approach to overcoming antibody-dependent as well as cellular rejection to the large animal models in this Program Project grant. Through the pipeline of small to large animal models, these studies will ultimately lead to the succesful induction of donor-specific T and B cell tolerance in human recipients with pre-existing antibodies to the heart or lung donor.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL018646-35
Application #
8459914
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
35
Fiscal Year
2013
Total Cost
$454,183
Indirect Cost
$139,765
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Smith, R N; Adam, B A; Rosales, I A et al. (2018) RNA expression profiling of renal allografts in a nonhuman primate identifies variation in NK and endothelial gene expression. Am J Transplant 18:1340-1350
Chatterjee, Debanjana; Moore, Carolina; Gao, Baoshan et al. (2018) Prevalence of polyreactive innate clones among graft--infiltrating B cells in human cardiac allograft vasculopathy. J Heart Lung Transplant 37:385-393
Gonzalez-Nolasco, Bruno; Wang, Mengchuan; Prunevieille, Aurore et al. (2018) Emerging role of exosomes in allorecognition and allograft rejection. Curr Opin Organ Transplant 23:22-27
Smith, R N; Matsunami, M; Adam, B A et al. (2018) RNA expression profiling of nonhuman primate renal allograft rejection identifies tolerance. Am J Transplant 18:1328-1339
Fan, Martin Y; Low, Jun Siong; Tanimine, Naoki et al. (2018) Differential Roles of IL-2 Signaling in Developing versus Mature Tregs. Cell Rep 25:1204-1213.e4
Benichou, Gilles; Prunevieille, Aurore (2018) Graft-derived exosomes. When small vesicles play a big role in transplant rejection. Am J Transplant 18:1585-1586
Marangoni, Francesco; Zhang, Ruan; Mani, Vinidhra et al. (2018) Tumor Tolerance-Promoting Function of Regulatory T Cells Is Optimized by CD28, but Strictly Dependent on Calcineurin. J Immunol 200:3647-3661
Fan, Martin Y; Turka, Laurence A (2018) Immunometabolism and PI(3)K Signaling As a Link between IL-2, Foxp3 Expression, and Suppressor Function in Regulatory T Cells. Front Immunol 9:69
Wang, Zhaohui; Louras, Nathan J; Lellouch, Alexandre G et al. (2018) Dosing optimization of CCR4 immunotoxin for improved depletion of CCR4+ Treg in nonhuman primates. Mol Oncol 12:1374-1382
Newton, Ryan H; Shrestha, Sharad; Sullivan, Jenna M et al. (2018) Maintenance of CD4 T cell fitness through regulation of Foxo1. Nat Immunol 19:838-848

Showing the most recent 10 out of 305 publications